Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Birmingham Polymers, Inc. was a specialized biotechnology company focused on the development and manufacture of biodegradable polymers for controlled-release drug delivery systems. Founded in 1990 and based in Birmingham, Alabama, the company became a leading supplier of poly(lactide-co-glycolide) (PLGA) and poly(lactide) (PLA) materials used in various pharmaceutical applications. Their expertise centered on creating customized polymer matrices to enhance the delivery of small molecules, peptides, and proteins. The company provided high-quality, medical-grade polymers to pharmaceutical and medical device companies globally. Birmingham Polymers was acquired by Southern Research Institute in 2000, and its technology and product lines were subsequently integrated into Durect Corporation's Lactel business. The company's contributions were instrumental in the advancement of long-acting injectable formulations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Birmingham Polymers.